<DOC>
	<DOCNO>NCT02633943</DOCNO>
	<brief_summary>This multi-center , long-term safety efficacy follow-up study subject hemoglobinopathy ( Î²-thalassemia severe sickle cell disease ) treat ex vivo gene therapy drug product bluebird bio-sponsored clinical study . After complete parent clinical study ( approximately 2 year ) , eligible subject follow additional 13 year total 15 year post-drug product infusion . No investigational drug product administer study .</brief_summary>
	<brief_title>Longterm Follow-up Subjects With Hemoglobinopathies Treated With Ex Vivo Gene Therapy</brief_title>
	<detailed_description />
	<mesh_term>Anemia , Sickle Cell</mesh_term>
	<mesh_term>Thalassemia</mesh_term>
	<mesh_term>Hemoglobinopathies</mesh_term>
	<mesh_term>beta-Thalassemia</mesh_term>
	<criteria>Provision write informed consent study subject , applicable , subject 's parent ( ) /legal guardian ( ) Treated drug product therapy hemoglobinopathy bluebird biosponsored clinical study Able comply study requirement Met VCN discontinuation criterion parent study</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>